| abstract |
The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and an N-(8-(2-hydroxybenzoyl)amino)caprylic acid salt. The invention further relates to processes for the preparation of such compositions, and their use in medicine. Claim 1: A pharmaceutical composition comprising a) 0.5 - 100 mg of EGF(A) derivative, b) 20 - 1000 mg, such as 50 - 600 mg, of a salt of the N-(8-(2 -hydroxybenzoyl)amino)caprylic acid and wherein said N-(8-(2-hydroxybenzoyl)amino)caprylic acid salt constitutes at least 90% w/w, such as at least 95% w/w of the excipients of the composition . |